IDEAS home Printed from https://ideas.repec.org/a/spr/aphecp/v15y2017i2d10.1007_s40258-016-0301-y.html
   My bibliography  Save this article

Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden

Author

Listed:
  • Åsa Ericsson

    (Novo Nordisk Scandinavia AB)

  • Adam Lundqvist

    (IHE, The Swedish Institute for Health Economics)

Abstract

Background Patients with uncontrolled type 2 diabetes mellitus (T2DM) are a priority group for intensified therapy without weight gain and with low risk of hypoglycaemia. Objective This study evaluates the cost effectiveness of insulin degludec plus liraglutide (IDegLira, Xultophy®) compared with six potential intensification treatment options for patients with T2DM that is uncontrolled with basal insulin. Methods The Swedish Institute for Health Economics (IHE) Cohort Model of Type 2 Diabetes was used with Swedish input data, a 40-year time frame and a societal perspective. The comparators for treatment intensification included insulin glargine, neutral protamine Hagedorn (NPH) insulin, insulin aspart plus either glargine or NPH, and liraglutide plus either glargine or NPH. Clinical data for all comparators (except NPH insulin) were based on an indirect treatment comparison of several studies. Prices were obtained from the 2014 Swedish Dental and Pharmaceutical Benefits Agency (Tandvårds- och läkemedelsförmånsverket [TLV]) database, and utility values were obtained from published studies. Sensitivity analyses were undertaken. Results Overall incremental cost-effectiveness ratios (ICER) were Swedish krona (SEK) 70,000 or lower per quality-adjusted life-year (QALY). IDegLira compared with intensified basal insulin showed an ICER of SEK 28,000 per QALY versus insulin glargine, SEK70,000 per QALY versus NPH insulin and SEK 60,000 per QALY versus NPH insulin plus liraglutide. IDegLira was dominant over insulin glargine plus liraglutide and insulin aspart plus insulin glargine or NPH insulin. Results were driven by the difference in glycated haemoglobin (HbA1c) reduction between treatments, as confirmed by sensitivity analyses. Conclusions IDegLira is estimated to be a cost-effective treatment in Sweden compared with commonly used intensification treatments for patients with T2DM uncontrolled with basal insulin.

Suggested Citation

  • Åsa Ericsson & Adam Lundqvist, 2017. "Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden," Applied Health Economics and Health Policy, Springer, vol. 15(2), pages 237-248, April.
    • Handle: RePEc:spr:aphecp:v:15:y:2017:i:2:d:10.1007_s40258-016-0301-y
    DOI: 10.1007/s40258-016-0301-y
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40258-016-0301-y
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40258-016-0301-y?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Adam Lundqvist & Katarina Steen Carlsson & Pierre Johansen & Emelie Andersson & Michael Willis, 2014. "Validation of the IHE Cohort Model of Type 2 Diabetes and the Impact of Choice of Macrovascular Risk Equations," PLOS ONE, Public Library of Science, vol. 9(10), pages 1-12, October.
    2. Adrian Bagust & Sophie Beale, 2005. "Modelling EuroQol health‐related utility values for diabetic complications from CODE‐2 data," Health Economics, John Wiley & Sons, Ltd., vol. 14(3), pages 217-230, March.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Dongzhe Hong & Lei Si & Minghuan Jiang & Hui Shao & Wai-kit Ming & Yingnan Zhao & Yan Li & Lizheng Shi, 2019. "Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review," PharmacoEconomics, Springer, vol. 37(6), pages 777-818, June.
    2. Pierre Johansen & Jonas Håkan-Bloch & Aiden R. Liu & Peter G. Bech & Sofie Persson & Lawrence A. Leiter, 2019. "Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada," PharmacoEconomics - Open, Springer, vol. 3(4), pages 537-550, December.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Michael Willis & Adam Fridhammar & Jens Gundgaard & Andreas Nilsson & Pierre Johansen, 2020. "Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Out," PharmacoEconomics, Springer, vol. 38(9), pages 953-969, September.
    2. Pierre Johansen & Jonas Håkan-Bloch & Aiden R. Liu & Peter G. Bech & Sofie Persson & Lawrence A. Leiter, 2019. "Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada," PharmacoEconomics - Open, Springer, vol. 3(4), pages 537-550, December.
    3. Åsa Ericsson & Divina Glah & Maria Lorenzi & Jeroen P Jansen & Adam Fridhammar, 2018. "Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes," PLOS ONE, Public Library of Science, vol. 13(2), pages 1-16, February.
    4. Richard F. Pollock & William J. Valentine & Steven P. Marso & Andreas Andersen & Jens Gundgaard & Nino Hallén & Deniz Tutkunkardas & Elizabeth A. Magnuson & John B. Buse, 2019. "Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)," Applied Health Economics and Health Policy, Springer, vol. 17(5), pages 615-627, October.
    5. Michael Willis & Pierre Johansen & Andreas Nilsson & Christian Asseburg, 2017. "Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM)," PharmacoEconomics, Springer, vol. 35(3), pages 375-396, March.
    6. Maria Alva & Alastair Gray & Borislava Mihaylova & Philip Clarke, 2014. "The Effect Of Diabetes Complications On Health‐Related Quality Of Life: The Importance Of Longitudinal Data To Address Patient Heterogeneity," Health Economics, John Wiley & Sons, Ltd., vol. 23(4), pages 487-500, April.
    7. Michael Laxy & Verena Maria Schöning & Christoph Kurz & Rolf Holle & Annette Peters & Christa Meisinger & Wolfgang Rathmann & Kristin Mühlenbruch & Katharina Kähm, 2019. "Performance of the UKPDS Outcomes Model 2 for Predicting Death and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus from a German Population-Based Cohort," PharmacoEconomics, Springer, vol. 37(12), pages 1485-1494, December.
    8. Melanie J. Davies & Divina Glah & Barrie Chubb & Gerasimos Konidaris & Phil McEwan, 2016. "Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting," PharmacoEconomics, Springer, vol. 34(9), pages 953-966, September.
    9. Phil McEwan & Jason Gordon & Marc Evans & Thomas Ward & Hayley Bennett & Klas Bergenheim, 2015. "Estimating Cost-Effectiveness in Type 2 Diabetes," Medical Decision Making, , vol. 35(5), pages 660-670, July.
    10. Scott Doyle & Andrew Lloyd & Lee Moore & Joshua Ray & Alastair Gray, 2012. "A Systematic Review and Critical Assessment of Health State Utilities," PharmacoEconomics, Springer, vol. 30(12), pages 1133-1143, December.
    11. Tessa Peasgood & Alan Brennan & Peter Mansell & Jackie Elliott & Hasan Basarir & Jen Kruger, 2016. "The Impact of Diabetes-Related Complications on Preference-Based Measures of Health-Related Quality of Life in Adults with Type I Diabetes," Medical Decision Making, , vol. 36(8), pages 1020-1033, November.
    12. Gemma Shields & Stephen Beard, 2015. "A Systematic Review of the Economic and Humanistic Burden of Gout," PharmacoEconomics, Springer, vol. 33(10), pages 1029-1047, October.
    13. Sara Stafford & Peter G. Bech & Adam Fridhammar & Nino Miresashvili & Andreas Nilsson & Michael Willis & Aiden Liu, 2022. "Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting," Applied Health Economics and Health Policy, Springer, vol. 20(4), pages 543-555, July.
    14. Hui Shao & Shuang Yang & Vivian Fonseca & Charles Stoecker & Lizheng Shi, 2019. "Estimating Quality of Life Decrements Due to Diabetes Complications in the United States: The Health Utility Index (HUI) Diabetes Complication Equation," PharmacoEconomics, Springer, vol. 37(7), pages 921-929, July.
    15. Ulf Persson & Michael Willis & Knut Ödegaard, 2010. "A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(2), pages 195-203, April.
    16. Phil McEwan & Hayley Bennett & Jonathan Fellows & Jennifer Priaulx & Klas Bergenheim, 2016. "The Health Economic Value of Changes in Glycaemic Control, Weight and Rates of Hypoglycaemia in Type 1 Diabetes Mellitus," PLOS ONE, Public Library of Science, vol. 11(9), pages 1-14, September.
    17. Alison J. Hayes & Philip M. Clarke & Merryn Voysey & Anthony Keech, 2011. "Simulation of Quality-Adjusted Survival in Chronic Diseases," Medical Decision Making, , vol. 31(4), pages 559-570, July.
    18. Chen-Wei Pan & Hong-Peng Sun & Hui-Jun Zhou & Qinghua Ma & Yong Xu & Nan Luo & Pei Wang, 2016. "Valuing Health-Related Quality of Life in Type 2 Diabetes Patients in China," Medical Decision Making, , vol. 36(2), pages 234-241, February.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:aphecp:v:15:y:2017:i:2:d:10.1007_s40258-016-0301-y. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.